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Abstract: Stored dried blood spots (DBS) can provide valuable samples for the retrospective
diagnosis of inborn errors of metabolism, and for validation studies for newborn blood spot
screening programs. Acylcarnitine species are subject to degradation upon long-term storage
at room temperature, but limited data are available on the stability in original samples and the
impact on acylcarnitine ratios. We analysed complete acylcarnitine profiles by flow-injection
tandem mass spectrometry in 598 anonymous DBS stored from 2013 to 2017, at +4 ◦C during
the first year and thereafter at room temperature. The concentrations of C2-, C3-, C4-, C5-, C6-,
C8-, C10:1-, C10-, C12:1-, C12-, C14:1-, C14-, C16:1-, C16-, C18:2-, C18:1-, C18-, C5OH+C4DC-,
C18:1OH-, and C16DC-carnitine decreased significantly, whereas a positive trend was found for free
carnitine. Only the C4/C8-, C8/C10-, C14:1/C10- and C14:1/C16-carnitine ratios appeared robust for
the metabolite instability. The metabolite instability may provoke the wrong interpretation of test
results in the case of retrospective studies and risk the inaccurate estimation of cut-off targets in
validation studies when only stored control DBS are used. We recommend including control DBS
in diagnostic, retrospective cohort studies, and, for validation studies, we recommend using fresh
samples and repeatedly re-evaluating cut-off targets.
Keywords: acylcarnitine; dried blood spot; inborn error of metabolism; metabolite instability;
metabolite stability; newborn blood spot screening; retrospective diagnosis; storage; tandem
mass spectrometry
1. Introduction
The development of tandem mass spectrometry (MS/MS) enabled rapid determination of
acylcarnitine and amino acid profiles [1,2]. This technique is commonly used in population newborn
bloodspot screening (NBS) to screen for disorders of mitochondrial fatty acid oxidation, and organic
acid and amino acid metabolism [3]. The primary process of NBS programs (e.g., screening panel,
sampling window, analytical techniques, storage time of filter paper cards and storage conditions)
varies worldwide, and even within countries [4,5]. In The Netherlands, 17 inborn errors of metabolism
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(IEM) are currently included in the NBS program [6]. The dried blood spots (DBS) on filter paper cards
are generally stored for a maximum period of five years after laboratory analysis [6].
Many IEMs are associated with unexpected death in early childhood, resulting from energy
deficiency or intoxication [7]. The often non-specific clinical presentations imply a risk of IEMs to
remain unrecognized as cause of death. Stored DBS can provide a valuable sample for post-mortem
investigations after unexpected death in early childhood [8–10]. This especially holds for countries,
where only a limited selection of IEMs is included in the NBS program and/or diagnostic resources are
scarce [4]. Moreover, stored DBS can be used for the evaluation of biomarkers of IEMs considered to
be included in the NBS program [11].
A study we recently performed on the prevalence of IEMs in children who died in early childhood,
using metabolite analysis in stored DBS, was complicated by the impact of long-term storage on the
acylcarnitine profiles. While the stability of C3DC-, C5DC-carnitine and saturated acylcarnitine species
has been analysed in stored, spiked DBS [12,13], the available data on acylcarnitine concentrations
in stored, original DBS are limited and only concern the stability of C3DC-, C0-, C2-, C3, C4,
and C5-carnitine [14–16]. Besides, the impact of metabolite stability on acylcarnitine ratios, which can
be used for diagnostic differentiation and characterization of IEMs [3], has never been assessed. Hence,
we systematically analysed the complete acylcarnitine profiles in original DBS stored from 2013 to
2017. Here, we report how metabolite instability can complicate the interpretation of retrospectively
analysed acylcarnitine biomarkers for IEMs in stored DBS, and reflect on the potential risks of using
control DBS stored at room temperature for validation studies for NBS programs.
2. Materials and Methods
The Medical Ethical Committee of the University Medical Center Groningen (Groningen,
The Netherlands) confirmed that the Medical Research Involving Human Subjects Act did not apply
and that official approval of this study by the Medical Ethical Committee was not required (METc code
2016/694). The Dutch NBS program is regulated by the National Institute for Public Health and the
Environment (Bilthoven, The Netherlands) (RIVM in Dutch). Its Research Committee on Neonatal
Screening (WONHS in Dutch) authorized the study. A waiver of consent was granted by both the
METc and WONHS, since the study concerned anonymized samples.
In The Netherlands, neonatal blood, sampled from the heel, is spotted on filter paper cards
between 72 and 168 h after birth and subsequently analysed in one of the five regional screening
laboratories, according to national protocols [6]. All filter paper cards were stored at +4 ◦C for one
year at the respective regional screening laboratory for quality assurance purposes. If authorized
by the parents, the filter paper cards were stored at room temperature for another four years at the
central archive of the RIVM reference laboratory, for quality assurance purposes and anonymized
retrospective biomarker studies. There was no conditioning of humidity. The cards were stored in
sealed bags (200–300 per bag) in cardboard boxes (20–30 bags per box). Once a year, in January of
calendar year “X”, all filter paper cards of calendar year “X-6” are destroyed [6]. If the parents object to
the use of residual anonymized blood samples for scientific research, the filter paper card is destroyed
after one year.
This study is part of a larger research project on the prevalence of IEMs in children who died
in early childhood. DBS included in the current study were from children with normal NBS results
(i.e., control samples in the aforementioned study). In October 2018 (start of study), the available
stored filter paper cards dated back to 2013. A total of 120 anonymized DBS on filter paper cards
per complete storage year, i.e., 2013 to 2017, were retrieved from the storage facilities of the RIVM,
resulting in five storage year cohorts (i.e., 2013, 2014, 2015, 2016 and 2017). Until analyses, the DBS
were kept in sealed bags with freshly added silica sachets, stored in a refrigerator at the laboratory
of Metabolic Diseases in Groningen, the Netherlands. The number of spots per year cohort, i.e., 120,
permits the nonparametric determination of reference intervals [17,18]. Filter paper cards of children
whose parents did not authorize the use for anonymous research purposes were excluded.
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Flow-injection MS/MS analysis was used to quantitatively determine the acylcarnitine profiles
in the DBS. Three 3.2 mm Ø discs were punched out of the DBS. Acylcarnitines were extracted
by vortexing for 30 min at 600 rpm after the addition of 6 deuterium-labeled internal standards in
methanol/MilliQ H2O (80/20 v/v). Supernatant was transferred to a vial and analyzed by flow-injection
tandem-mass spectrometry (Sciex API4500, Framingham, MA, USA). Concentrations of C0 and the
individual acylcarnitines were quantified by multiple reaction monitoring. C0 by an m/z transition
of 162 ≥ 103 and acylcarnitines by selected precursor ions with m/z 85 as the common product ion,
as described previously [19]. Data evaluation was performed with Analyst® MD 1.6.2 Instrument
Control and Data Processing Software (Sciex, Framingham, MA, USA). The measurements took place
between November 2018 and July 2019. Quality control specimens were analysed parallel with the
study samples to monitor the precision during the study period. Concentrations were expressed in
micromole per liter, with two decimal places.
Data analysis was performed using SIMCA Software, version 15.0.2 (Umetrics, Umea, Sweden),
Microsoft Excel with the Analyse-it add-in, version 4.81.6, and IBM SPSS Statistics for Windows,
version 23 (IBM Corporation, Armonk, NY, USA). GraphPad Prism, version 5.0 (GraphPad Software,
La Jolla, CA, USA) was used to create graphs. First, a principal component analysis was used to
visualize and explore the complete dataset. Cases outside the 99% Hotelling’s T2 range were identified
as strong outliers and excluded from further data analysis. Next, the distributions of the acylcarnitine
concentrations and their molar ratios per storage year cohort were assessed. Jonckheere’s trend test
was used to test for significant trends upon storage duration, a p-value of <0.05 was considered
statistically significant. The test was not applied when >50% of the cases had concentrations at or below
the detection limit (i.e., <0.01–0.05, depending on acylcarnitine species investigated), when >50%
of the cases concerned zero or infinite values for molar ratios, or when a visual trend was absent.
For the acylcarnitine species with a significant change in the concentration upon long-term storage,
regression analysis was used to define the trend. For linear trends, the annual decay rates were
estimated from the slope of the trend line equations. The four-year percent decays were calculated
from the estimated decay rates and the median acylcarnitine concentrations in 2017. For other trend
types, we calculated the four-year percent decays from the difference in the median concentrations in
2017 and 2013. Finally, we evaluated the possible consequences of metabolite instability for adequate
interpretation of acylcarnitine biomarkers for IEMs upon long-term storage room temperature. To this
aim, we investigated the potential impact on (1) retrospective MS/MS analysis in stored DBS for the
detection of IEMs, and (2) validation studies in stored control DBS to determine cut-off targets for
NBS programs.
3. Results
A total of 598 DBS were analysed; 119 DBS from storage years 2013 and 2014 and 120 DBS from
storage years 2015–2017. The data of the low- and high-quality control samples per acylcarnitine species
are depicted in Table S1. The mean inter-assay coefficient of variation was <20% for all acylcarnitine
species, except for some acylcarnitines (i.e., unsaturated-, hydroxy-, dicarboxylic, and very long-chain
acylcarnitine species) with concentrations close to the detection limit. Upon outlier detection via
principal component analysis (n = 598, four components, UV scaling, cumulative R2X = 0.536;
cumulative Q2 = 0.373), 20 cases were excluded from the dataset (i.e., 2014: n = 6/119; 2015: n = 6/120;
2016: n = 1/120; 2017: n = 7/120).
The changes in carnitine and acylcarnitine concentrations per storage year cohort are presented
in Figure 1. Jonckheere’s trend test revealed a significant negative trend upon long-term storage for
C2-, C3-, C4-, C5-, C6-, C8-, C10:1-, C10-, C12:1-, C12-, C14:1-, C14-, C16:1-, C16-, C18:2-, C18:1-, C18-,
C5OH + C4DC-, C18:1OH-, and C16DC-carnitine concentrations. A positive trend was found for free
carnitine. The total carnitine concentration (i.e., the sum of acylcarnitines plus free carnitine) did not
change upon long-term storage.
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Using regression analysis, the trend type for free carnitine was defined as polynomial, whereas,
for C2- and C3-carnitine the trend appeared exponential. For the remaining acylcarnitine species,
the trend was defined as linear. The estimated decays of the acylcarnitine species are presented in
Table S2. The observed decreases in absolute concentrations between 2017 and 2013 were greatest
for C2-, C3-, C16-, C18:1, C18-carnitine. The most substantial percentual drop in concentrations was
found for C2-, C3-, C6-, C5OH + C4DC-, and C18:1OH-carnitine, with estimated four-year decays
above 60%. The estimated four-year decay ranged between 22% and 34% for the remaining saturated
acylcarnitines, and between 30% and 45% for the unsaturated acylcarnitines and C16DC-carnitine.
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Figure 1. Changes in carnitine and acylcarnitine concentrations. The impact of metabolite instability 
upon long-term storage at room temperature. The boxplots represent the first quartile, median and 
third quartile. The whiskers extend to the 2.5th and 97.5th percentiles. Individual dots represent non-
extreme outliers. Shaded areas represent the reference ranges as determined by our centre for the 
neonatal population. For C5:1-, C12OH-, C14OH-, C16OH-, and C18OH-, C6DC-, C16DC-, C18DC-, 
C24-, and C26-carnitine, the upper reference limit is below the detection limit (i.e., not detectable). * 
Statistically significant trend in the concentration upon storage duration, as determined by 
Jonckheere’s trend test. The following parameters were excluded from statistical analysis: C5:1-, 
C4OH + C3DC-, C5DC-, C6DC-, C12OH-, C14OH-, C16OH-, C18OH-, C18DC-, C24-, and C26-
carnitine. 
The impact of long-term storage on the molar ratios of acylcarnitine species is depicted in Figure 
2. The C14:1/C12:1 ratio was excluded from statistical analysis because of infinite values in >50% of 
the data entries. Only the C4/C8-, C8/C10-, and C14:1/C16-carnitine ratios did not demonstrate a 
significant trend upon long-term storage, as determined by Jonckheere’s trend test. The C14:1/C10-
carnitine ratio, though statistically significant, did not show a visual trend. The percentual decays of 
the individual acylcarnitines in these ratios were similar (i.e., the absolute difference in the estimated 
percent decays was <5%). Therefore, these ratios were assessed as robust with regard to the impact 
of metabolite instability upon long-term storage at room temperature. 
Figure 1. Changes in carnitine and acylcarnitine concentrations. The impact of metabolite instability
upon long-term storage at room temperature. The boxplots represent the first quartile, median and
third quartile. The whiskers extend to the 2.5th and 97.5th percentiles. Individual dots represent
non-extreme outliers. Shaded areas represent the reference ranges as determined by our centre for the
neonatal population. For C5:1-, C12OH-, C14OH-, C16OH-, and C18OH-, C6DC-, C16DC-, C18DC-,
C24-, and C26-carnitine, the upper reference limit is below the detection limit (i.e., not detectable).
* Statistically significant trend in the concentration upon storage duration, as determined by Jonckheere’s
trend test. The following parameters were excluded from statistical analysis: C5:1-, C4OH + C3DC-,
C5DC-, C6DC-, C12OH-, C14OH-, C16OH-, C18OH-, C18DC-, C24-, and C26-carnitine.
The impact of long-term storage on the molar ratios of acylcarnitine species is depicted in Figure 2.
The C14:1/C12:1 ratio was excluded from statistical analysis because of infinite values in >50% of the
data entries. Only the C4/C8-, C8/C10-, and C14:1/C16-carnitine ratios did not demonstrate a significant
trend upon long-term storage, as determined by Jonckheere’s trend test. The C14:1/C10-carnitine ratio,
though statistically significant, did not show a visual trend. The percentual decays of the individual
acylcarnitines in these ratios were similar (i.e., the absolute difference in the estimated percent decays
was <5%). Therefore, these ratios were assessed as robust with regard to the impact of metabolite


















Figure 2. Changes in the molar ratios of carnitine and acylcarnitines. The impact of metabolite instability
upon long-term storage at room temperature. The boxplots represent the first quartile, median and
third quartile. The whiskers extend to the 2.5th and 97.5th percentiles. Individual dots represent
non-extreme outliers. Shaded areas represent the reference ranges as determined by our centre for the
neonatal population. For C14:1/C12:1, no reference range is available because of too many infinite
values. For C16OH/C16 and C18OH/C18, the upper reference limit is 0.0. * Statistically significant trend
in the molar ratio upon storage duration, as determined by Jonckheere’s trend test. The following ratios
were excluded from statistical analysis: C5/C0-, C14:1/C12:1-, C16OH/C16-, and C18OH/C18-carnitine.
The metabolite instability increases the likelihood of wrong interpretation of acylcarnitine
biomarkers for IEMs in DBS stored at room temperature. Tables 1 and 2 present the potential risks for
the detection of IEMs upon retrospective MS/MS analysis, and for validation studies in stored control
DBS to determine cut-off targets for NBS programs.
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Risk Category Potential Effect onCutoff Target
C0 (low) CUD False-negative Too high
C0 (high) CPT-I False-positive Too high
C2 (low) CUD, CPT-II False-positive Too low
C3 (low) CUD False-positive Too low
C3 (high) PROP, MUT, Cbl A-D False-negative Too low
C4 SCAD, EE, IBG, FIGLU
a,
MADD False-negative Too low
C5 IVA, MADD, 2MBG, EE False-negative Too low
C6 MCAD, MADD False-negative Too low
C8 MCAD, MADD False-negative Too low
C10:1 MCAD False-negative Too low
C10 MADD, MCAD False-negative Too low
C12:1 MADD, VLCAD False-negative Too low
C12 MADD, CPT-II, CACT,VLCAD False-negative Too low
C14:1 VLCAD, MADD,LCHAD/TFP False-negative Too low
C14 MADD, CPT-II, VLCAD,CACT, LCHAD/TFP False-negative Too low
C16:1 VLCAD, LCHAD/TFP,CACT, CPT-II False-negative Too low
C16 (low) CPT-I, CUD False-positive Too low
C16 (high) CACT, CPT-II False-negative Too low
C18:2 (low) CPT-I False-positive Too low
C18:2 (high) CPT-II, CACT False-negative Too low
C18:1 (low) CPT-I, CUD False-positive Too low
C18:1 (high) CPT-II, CACT False-negative Too low
C18 (low) CPT-I, CUD False-positive Too low






C18:1OH LCHAD/TFP False-negative Too low
C16DC PBD False-negative Too low
The potential consequences associated with (1) the interpretation of retrospectively analysed carnitine and
acylcarnitine concentrations in DBS upon long-term storage at room temperature for the detection of IEMs,
and (2) using control DBS stored at room temperature for validation studies on cut-off targets for NBS programs.
a FIGLU is only associated with a high C4-carnitine when butylation is applied. Abbreviations (in alphabetical
order): 2M3HBA, 2-methyl-3-hydroxybutyric aciduria (i.e., alpha-methylacetoacetic aciduria; online mendelian
inheritance in man (OMIM) #203750); 2MBG, 2-short/branched chain acyl-CoA dehydrogenase deficiency (# 610006);
3MCC, 3-methylcrotonyl-CoA carboxylase deficiency (#210200, #210210); 3MGA, 3-methylglutaconic aciduria
(#250950, #302060); BKT, beta-ketothiolase deficiency (#203750); BTD, biotinidase deficiency (#253260); CACT,
carnitine-acylcarnitine translocase deficiency (#212138); Cbl, cobalamin deficiency (complementation group); CPT-I,
carnitine palmitoyltransferase I deficiency (#255120); CPT-II, carnitine palmitoyltransferase II deficiency (#255110);
CUD, carnitine uptake defect (#212140); EE, ethylmalonic encephalopathy (#602473); FIGLU, formiminoglutamic
aciduria (#229100); IBG, isobutyryl-CoA dehydrogenase deficiency (#611283); IVA, isovaleryl-CoA dehydrogenase
deficiency (#243500); HMG, 3-hydroxy-3-methylglutaric aciduria (#246450); LCHAD, long-chain L-3-Hydroxy
dehydrogenase deficiency (#609016); MADD, multiple acyl-CoA dehydrogenase deficiency (#231680); MCAD,
medium-chain acyl-CoA dehydrogenase deficiency (#607008); MCD, holocarboxylase synthetase deficiency (#253270);
MUT, methylmalonic aciduria (#251000, 251100, 251110); PBD, peroxisome biogenesis disorder (complementation
group); PROP, propionic aciduria (#606054); SCAD, short-chain acyl-CoA dehydrogenase deficiency (#201470); TFP,
trifunctional protein deficiency (#609015); VLCAD, very long-chain acyl-CoA dehydrogenase deficiency (#201475).
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Table 2. Potential impact of metabolite instability on the interpretation of carnitine and acylcarnitine ratios.
Molar Ratio Disorder a
Retrospective Analysis of IEMs Validation Studies for NBS Programs
Risk Category Potential Effect on Cutoff Target
C0/(C16 + C18) (low) CPT-II, CACT False-negative Too high
C0/(C16 + C18) (high) CPT-I False-positive Too high
C3/C2 PROP, MUT, Cbl A-D, MCD False-positive Too high
C3/C16 PROP, MUT, Cbl A-D, CPT-I, MCD False-negative Too low
C4/C2 SCAD, MADD, IBG, EE, FIGLU b False-positive Too high
C4/C3 (low) MCD, Cbl A-D, PROP False-negative Too high
C4/C3 (high) EE, IBG, FIGLU b, MADD, SCAD False-positive Too high
C4/C8 IBG, SCAD, EE, FIGLU b None, similar percent decay of the involved acylcarnitine species
C5/C2 IVA, MADD, 2MBG, EE False-positive Too high
C5/C3 (low) MCD, MUT, Cbl A-B, PROP False-negative Too high
C5/C3 (high) IVA, MADD, EE, 2MBG False-positive Too high
C8/C2 MCAD, MADD False-positive Too high
C8/C10 MCAD None, similar percent decay of the involved acylcarnitine species
C14:1/C2 VLCAD, MADD, LCHAD/TFP False-positive Too high
C14:1/C10 VLCAD Appears negligible, negative statistical trend, but no visual trend and similarpercent decay of the involved acylcarnitine species
C14:1/C16 VLCAD, MADD, LCHAD/TFP None, similar percent decay of the involved acylcarnitine species
(C16 + C18:1)/C2 (low) CPT-I False-negative Too high
(C16 + C18:1)/C2 (high) CPT-II, CACT False-positive Too high
The potential consequences associated with (1) the interpretation of retrospectively analysed carnitine and acylcarnitine ratios in DBS upon long-term storage at room temperature for the
detection of IEMs, and (2) using control DBS stored at room temperature for validation studies on cut-off targets for NBS programs. Shaded rows represent the ratios that appear robust for
the metabolite instability. The percent decays were defined as similar if the absolute difference in the estimated percent decays was <5%. The C14:1/C12:1 ratio was excluded from analysis
because of infinite values in >50% of the data entries. a See caption of Table 1 for the defined abbreviations. b FIGLU is only associated with a high C4-carnitine when butylation is applied.
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4. Discussion
Since the development of MS/MS analysis, several studies have reported on the instability of
acylcarnitines upon long-term storage at room temperature. However, limited data are available on
the decay in original samples, and the impact on acylcarnitine ratios and the associated risks of using
common cut-off values for the interpretation of acylcarnitine profiles, have never been systematically
assessed [12–15]. In this study, upon long-term storage at room temperature, we found a decrease
in the measured concentrations of short-, medium-, and long-chain acylcarnitines of saturated and
unsaturated fatty acids, while free carnitine increased. The total carnitine concentration remained
similar throughout the years of storage. Likely, the acylcarnitine species are hydrolysed to free carnitine
upon long-term storage at room temperature. The different decay rates of acylcarnitine species have a
substantial impact on many molar ratios. In fact, only the C4/C8-, C8/10-, and C14:1/C16-carnitine
ratios, and C14:1/C10-carnitine ratio, appeared robust for the metabolite instability.
In the case of retrospective, diagnostic analysis, metabolite instability may provoke false-positive
and false-negative test results. Feasible identification of IEMs depends on the stability of the
disease-related metabolite combined with its initial concentration and the significance of the
elevation of the characteristic metabolite to the corresponding cut-off value. For many acylcarnitine
biomarkers, at least the 1st to 10th percentile of the disorder range (or the 90th to 100th percentile
in case of low cut-off targets) overlaps with reference intervals for the healthy population [3].
This interference, and thus the likelihood of overlooking an IEM, increases upon greater metabolite
instability. Based on our results, the most adverse effects for reliable detection are expected
for IEMs associated with accumulations of C3- and C5OH + C4DC-carnitine and free carnitine
(e.g., propionic aciduria and methylmalonic aciduria; and 3-methylcrotonyl-CoA carboxylase deficiency,
3-hydroxy-3-methylglutaric aciduria, holocarboxylase synthetase deficiency, beta-ketothiolase
deficiency; carnitine palmitoyltransferase I deficiency), and in case molar ratios are used as a
primary screening test such as C14:1/C2, C0/(C16 + C18) and (C16/C18:1)/C2 (e.g., very long-chain
acyl-CoA dehydrogenase deficiency; carnitine palmitoyltransferase I deficiency; and carnitine
palmitoyltransferase II deficiency, carnitine-acylcarnitine translocase deficiency). Additionally, since
>75% of the C5DC-carnitine measurements were below the detection limit, there appears to be a
considerable impact on the retrospective diagnosis of glutaric aciduria type I. The detection of a
carnitine uptake defect seems complicated by the substantial rise in free carnitine, but the sum of
acylcarnitines (and free carnitine) may still enable the diagnosis [13]. In line with previous studies,
the impact of metabolite instability appears relatively limited for the detectability of IEMs associated
with saturated medium- and long-chain acylcarnitine accumulations, and when compared to the
degradation of galactose-1-phosphate uridyltransferase and biotinidase activities [13,20]. In case of
retrospective, diagnostic analysis, examination of the complete acylcarnitine profile may allow for an
estimate of the metabolite instability. This would improve the interpretation of potential deviations
and could reveal outliers that would otherwise not have been discovered. Especially in areas where
the NBS panel is small and/or diagnostic resources are limited, this may be relevant. For diagnostic,
retrospective cohort studies, we recommend including control DBS.
Caution is warranted when control DBS stored at room temperature are used for validation
studies of NBS programs, because of the risk on incorrect estimation of reference ranges and cut-off
targets. This particularly applies when, given their rarity, the storage conditions for samples of IEM
cases for comparison analysis are different (e.g., frozen, different storage time). For validation studies,
we therefore advocate using fresh control samples and comparing them to carefully stored samples of
IEM cases and controls. Additionally, we emphasize the importance of repeated re-evaluation of a
metabolite’s cut-off target after its introduction to the NBS panel.
Metabolite stability is affected by storage conditions. Increased temperature, humidity and
sunlight exposure are known to influence sample integrity. This also accounts for other analytes used
in NBS programs, such as amino acids, endocrine and enzyme markers [13,16,20–22]. Our results
emphasize the importance of obtaining background information on a sample’s storage conditions.
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Whereas storage at room temperature over a two-year period results in substantial changes in the
concentrations of several acylcarnitine and amino acid species, these changes are attenuated or not
present upon storage at −20 or −80 ◦C [16]. To minimize metabolite instabilities, DBS storage at low
humidity (<30%) and under frozen conditions (≤−20 ◦C) is recommended [13,16,20,22,23]. Moreover,
during transport, the temperature and humidity should preferentially be minimized as much as
possible [20]. Additionally, for optimal interpretation, the condition of the patient at the time of
sample collection needs to be taken into account. For example, the subject’s age, metabolic stress and
post-mortem sample obtainment can have a considerable impact on a metabolite profile [9,24].
Some study limitations deserve discussion. First, the initial acylcarnitine profiles are unknown
due to the required anonymization procedures. This limited calculation of the true percent decays,
which were instead estimated from the median concentrations in 2017. Second, there is a variation
in the stability data because (1) the exact storage time of the individual DBS is unknown due to the
required anonymization, and (2) the longitudinal timing of our analyses. There is evidence that suggests
a more rapid degradation during the first months of storage at room temperature, which eventually
slows down [12,13]. Therefore, the total decay might even be larger than the presented estimations,
especially since the samples in our cohort were stored in a refrigerator without silica during the first
year. Third, disparity in DBS quality and punch location are also important contributors to variation in
analyte concentrations [25]. Fourth, it is unknown whether the efficiency of extraction of metabolites
from filter paper cards changes upon the long-term storage of DBS. Possible effects on extractability
do, however, not invalidate our findings, as the potential consequences coincide with the impact
of metabolite instability. Finally, we had no access to NBS samples of diagnosed patients that were
stored under the same conditions in order to validate the claimed risks presumably associated with the
detection of IEMs in DBS upon long-term storage at room temperature.
In conclusion, acylcarnitine profiles in DBS stored at room temperature are subject to metabolite
instability. In case of diagnostic, retrospective cohort studies, we recommend including control DBS.
For validation studies, we recommend using fresh samples and to repeatedly re-evaluate cut-off targets.
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